Addressing Market Access Challenges As CGTs Expand To Larger Patient Populations

The first wave of cell and gene therapies (CGTs) primarily targeted smaller, often rare disease populations, establishing their transformative potential. Now, as CGTs advance into treating conditions affecting much larger patient groups, a new wave of market access challenges emerges. The sheer scale magnifies payer concerns about budget impact, necessitates more sophisticated value demonstration beyond clinical data alone, and accelerates the need to potentially integrate these complex treatments into broader care settings, like outpatient clinics.

Manufacturers must evolve their strategies to meet these scaled-up demands. Discover forward-thinking strategies to navigate this dynamic environment – continue reading below.